Home Forums |
|
Clinical Trials Considering or participating in research studies |
![]() |
|
Thread Tools | Search this Thread |
#1
|
|||
|
|||
Responses to TLK199
Hi All,
Now researchers report that underexpression of a special gene set - the JNK gene set - perhaps may identify patients likely to respond to Ezatiostat (TLK199). C-Jun NH2-terminal kinase (JNK) is implicated in transformation to cancer. The abstract is complicated – you will find the important info in this sentence: The expression data confirms that patients whose pre-therapy marrow shows under-expression of the JNK gene set are precisely those who benefit from this drug therapy and those patients who already over-express these genes are unlikely to respond. http://ash.confex.com/ash/2011/webpr...aper37656.html This kind of research is very important and we hope they at last will find out the best treatment for all MDS patients. Patients with the 5q- will often respond to Revlimid, patients with lower DNA methylation of the WT1 gene will perhaps have a better response to Vidaza and patients with underexpression of the JNK gene set will eventually respond to Ezatiostat. Kind regards Birgitta-A |
![]() |
Thread Tools | Search this Thread |
|
|
![]() |
||||
Thread | Thread Starter | Forum | Replies | Last Post |
ASH 2010 Hematologic Responses in MDS Patients - Deferasirox/Exjade | akita | Transfusions and Iron Overload | 0 | Fri Dec 10, 2010 04:14 PM |
Ezatiostat HCL (TLK199 tablets) - A Novel glutathione analog prodrug for MDS | S001 | Drugs and Drug Treatments | 4 | Tue Nov 30, 2010 06:46 PM |
Results with TLK199 | Birgitta-A | Drugs and Drug Treatments | 0 | Tue Aug 4, 2009 07:34 AM |
Vidaza for my 85 yr old mother with MDS? | Francine S | MDS | 15 | Tue Dec 16, 2008 11:30 AM |
Tlk199 | Jordan | Clinical Trials | 9 | Sun Oct 19, 2008 01:23 PM |